RxDoctor Payments Data

Michelle Berry, DO

Family Medicine · Boerne, TXNPI 1033194527

Payments from drug & device makers

$10,229in general payments, 2019–2025

Across 550 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$995
  • AstraZeneca$992
  • Pfizer$868
  • Amarin Pharma, Inc.$594
  • Otsuka America Pharmaceutical, Inc.$528
  • plus $5K from 43 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$9,98398%
  • Education$2282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,229 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$123,850
Medicare patients
206
Services billed
1,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$98,994
XareltoRivaroxaban24$39,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$35,228
TrulicityDulaglutide20$25,539
JardianceEmpagliflozin14$23,154
FarxigaDapagliflozin Propanediol14$20,272
EliquisApixaban29$19,173
VascepaIcosapent Ethyl20$16,054
MyrbetriqMirabegron25$14,019
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,864
InvokanaCanagliflozin11$8,464
SynthroidLevothyroxine Sodium36$4,243
Midodrine Hcl13$3,459
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,003
Atorvastatin Calcium257$2,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$995$98,99472 claims
Johnson & JohnsonXarelto, Invokana$471$47,87035 claims
GSKTrelegy Ellipta$359$35,22842 claims
AstraZenecaFarxiga, Breztri Aerosphere$992$31,13531 claims
Lilly USA, LLCTrulicity$232$25,53920 claims
Boehringer IngelheimJardiance$35$23,15414 claims
PfizerEliquis$868$19,17329 claims
Astellas Pharma US IncMyrbetriq$208$14,01925 claims
AbbVieSynthroid$1,389$4,24336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →